NBP net incomeFY2025-$46.27M
NBP net income was -$46.27M for fiscal 2025 (ended Dec 31, 2025), compared with -$22.23M in fiscal 2024.
NovaBridge Biosciences (NBP) financials
For fiscal 2025 (ended Dec 31, 2025), NovaBridge Biosciences reported -$46.27M of net income.
- Net income, FY2025
- -$46.27M
- Free cash flow, FY2025
- -$20.60M
- EPS, diluted, FY2025
- -$0.21
- Cash
- $210.63M
- Market cap
- $104.8M
FY2019FY2023
FY2019FY2025
FY2019FY2025
NBP revenue and earnings growth
NBP EPSFY2025-$0.21
NBP diluted EPS was -$0.21 for fiscal 2025 (ended Dec 31, 2025), compared with -$0.12 in fiscal 2024.
NBP free cash flowFY2025-$20.60M
NBP free cash flow was -$20.60M for fiscal 2025 (ended Dec 31, 2025), compared with -$52.72M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | $632.0K | -$1.55M | $13.81M | $236.42M | $4.31M |
| Cost of revenue | - | - | - | $3.95M | $7.29M | - | - |
| Gross profit | - | - | - | -$5.50M | $6.53M | - | - |
| Research and development | $62.91M | $21.77M | $21.45M | $22.55M | $190.34M | $150.91M | $120.72M |
| Selling, general and admin | $31.36M | $29.66M | $28.16M | $28.98M | $141.22M | $61.67M | $94.02M |
| Operating income | -$94.27M | -$51.43M | -$72.02M | -$53.08M | - | - | - |
| Interest expense | - | - | $102.0K | $1.0K | $0 | $147.0K | $430.0K |
| Pre-tax income | -$88.34M | -$49.70M | -$82.22M | -$141.10M | -$366.37M | $74.04M | -$208.56M |
| Income tax | $0 | $0 | $0 | $103.0K | -$495.0K | $1.87M | - |
| Net income | -$46.27M | -$22.23M | -$207.73M | -$371.05M | -$365.87M | $72.17M | -$208.56M |
| EPS, basic | -$0.21 | -$0.12 | -$1.09 | -$1.96 | -$2.09 | $0.54 | -$28.90 |
| EPS, diluted | -$0.21 | -$0.12 | -$1.09 | -$1.96 | -$2.09 | $0.46 | -$28.90 |
| Diluted shares | 220.3M | 186.7M | 191.4M | 189.8M | 174.7M | 157.2M | 7.4M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $210.63M | $68.26M | $291.51M | $475.37M | $552.67M | $746.76M | $182.88M |
| Short-term investments | $210.0K | $105.14M | $20.22M | $34.13M | $118.19M | $4.83M | $4.60M |
| Receivables | - | - | - | $0 | $5.19M | $20.00M | - |
| Inventory | - | - | - | $0 | $4.27M | - | - |
| Current assets | $217.52M | $176.69M | $329.91M | $525.79M | $750.36M | $818.95M | $195.54M |
| Goodwill | - | - | - | $23.57M | $25.51M | $24.92M | $23.35M |
| Total assets | $260.52M | $212.68M | $368.92M | $590.63M | $878.95M | $970.70M | $249.59M |
| Current liabilities | $26.89M | $8.45M | $58.14M | $109.92M | $97.92M | $88.30M | $84.53M |
| Short-term debt | - | - | $4.22M | $2.75M | - | - | $7.18M |
| Long-term debt | - | - | - | - | - | - | $9.80M |
| Total debt | - | - | - | - | - | - | $16.98M |
| Total liabilities | $29.58M | $11.52M | $126.34M | $168.73M | $163.45M | $108.30M | $95.96M |
| Shareholders' equity | $230.94M | $201.16M | $242.58M | $417.81M | $715.15M | $862.40M | -$292.26M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$20.60M | -$52.67M | -$72.70M | -$49.58M | -$152.70M | $66.45M | -$124.68M |
| Capital expenditures | $7.0K | $48.0K | $164.0K | $2.09M | $4.70M | $1.23M | $1.76M |
| Free cash flow | -$20.60M | -$52.72M | -$72.86M | -$51.67M | -$157.40M | $65.22M | -$126.44M |
| Investing cash flow | $104.97M | -$136.01M | -$15.16M | -$5.18M | -$114.11M | -$30.94M | $30.52M |
| Financing cash flow | $57.73M | -$335.0K | -$8.24M | $3.91M | $93.20M | $527.28M | $21.94M |
| Stock-based compensation | $5.97M | -$1.95M | $10.24M | $13.15M | $95.50M | $75.63M | $52.70M |
| Depreciation and amortization | - | $300.0K | $500.0K | $200.0K | - | - | - |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | -111.2% | -94.2% | 5386.7% | - |
| Gross margin | - | - | - | - | 47.3% | - | - |
| Operating margin | - | - | -11395.1% | - | - | - | - |
| Net margin | - | - | -32868.5% | - | -2648.7% | 30.5% | -4840.1% |
| Free cash flow margin | - | - | -11528.6% | - | -1139.5% | 27.6% | -2934.2% |
| Return on equity | -20.0% | -11.1% | -85.6% | -88.8% | -51.2% | 8.4% | - |
| Return on assets | -17.8% | -10.5% | -56.3% | -62.8% | -41.6% | 7.4% | -83.6% |
| Current ratio | 8.09 | 20.90 | 5.67 | 4.78 | 7.66 | 9.28 | 2.31 |
Source: XBRL data NovaBridge Biosciences files with the SEC, latest filing dated Apr 7, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
NBP peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| NBP | - | - | -$46.27M | - | $104.8M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
NBP FAQ
6 questionsIs NBP profitable?
No. NovaBridge Biosciences reported a net loss of $46.27M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does NBP have?
NovaBridge Biosciences reported $210.63M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is NBP free cash flow?
NovaBridge Biosciences generated -$20.60M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$20.60M less capital expenditures.What is NBP earnings per share?
Diluted earnings per share were -$0.21 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did NBP last report financial results?
The latest statements here come from NovaBridge Biosciences's 20-F filed on Apr 7, 2026, covering the period ended Dec 31, 2025.Where does this NBP financial data come from?
Quantisnow builds these statements from the structured XBRL data NovaBridge Biosciences files with the SEC. It is provided for information only and is not investment advice.